These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 15767641)

  • 41. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
    N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors predicting response to EGFR tyrosine kinase inhibitors.
    Engelman JA; Jänne PA
    Semin Respir Crit Care Med; 2005 Jun; 26(3):314-22. PubMed ID: 16052433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
    Zhang X; Chang A
    J Med Genet; 2007 Mar; 44(3):166-72. PubMed ID: 17158592
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for EGFR mutations in lung cancer, a report from India.
    Sahoo R; Harini VV; Babu VC; Patil Okaly GV; Rao S; Nargund A; Venkataswamy E; Rao R; Kumar BS
    Lung Cancer; 2011 Sep; 73(3):316-9. PubMed ID: 21315473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
    Amler LC; Goddard AD; Hillan KJ
    Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    Uramoto H; Mitsudomi T
    Br J Cancer; 2007 Mar; 96(6):857-63. PubMed ID: 17325698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
    Miller VA
    Semin Oncol Nurs; 2008 Feb; 24(1):27-33. PubMed ID: 18222149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
    Murray S; Dahabreh IJ; Linardou H; Manoloukos M; Bafaloukos D; Kosmidis P
    J Thorac Oncol; 2008 Aug; 3(8):832-9. PubMed ID: 18670300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
    Santarpia M; De Pas TM; Altavilla G; Spaggiari L; Rosell R
    Future Oncol; 2013 Mar; 9(3):327-45. PubMed ID: 23469969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
    Bronte G; Rolfo C; Giovannetti E; Cicero G; Pauwels P; Passiglia F; Castiglia M; Rizzo S; Vullo FL; Fiorentino E; Van Meerbeeck J; Russo A
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):300-13. PubMed ID: 24041630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi A; Pasquale R; Esposito C; Normanno N
    Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
    Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
    Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
    Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
    Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
    Herbst RS; Bunn PA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
    Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 58. Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
    Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A
    Arch Bronconeumol; 2013 Feb; 49(2):79-81. PubMed ID: 22627040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
    Ou SH
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):407-21. PubMed ID: 22257651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
    Pallis AG; Syrigos KN
    Lung Cancer; 2013 May; 80(2):120-30. PubMed ID: 23384674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.